Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics


Rigel Pharmaceuticals, Inc. (RIGL): $1.25

0.12 (+10.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RIGL POWR Grades


  • Quality is the dimension where RIGL ranks best; there it ranks ahead of 91.6% of US stocks.
  • The strongest trend for RIGL is in Stability, which has been heading down over the past 179 days.
  • RIGL's current lowest rank is in the Stability metric (where it is better than 5.88% of US stocks).

RIGL Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for RIGL is 4.91 -- better than 91.87% of US stocks.
  • Price to trailing twelve month operating cash flow for RIGL is currently 91.42, higher than 94.93% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of -21.8%, Rigel Pharmaceuticals Inc's debt growth rate surpasses only 18.43% of about US stocks.
  • Stocks that are quantitatively similar to RIGL, based on their financial statements, market capitalization, and price volatility, are SEAC, TCON, ALLT, GEOS, and ARAY.
  • Visit RIGL's SEC page to see the company's official filings. To visit the company's web site, go to www.rigel.com.

RIGL Valuation Summary

  • In comparison to the median Healthcare stock, RIGL's price/sales ratio is 60.35% lower, now standing at 4.5.
  • RIGL's price/sales ratio has moved down 11.1 over the prior 243 months.
  • RIGL's EV/EBIT ratio has moved down 148 over the prior 243 months.

Below are key valuation metrics over time for RIGL.

Stock Date P/S P/B P/E EV/EBIT
RIGL 2021-08-31 4.5 9.5 -84.0 -156.5
RIGL 2021-08-30 4.5 9.5 -84.0 -156.5
RIGL 2021-08-27 4.5 9.6 -84.6 -157.9
RIGL 2021-08-26 4.4 9.3 -82.2 -153.0
RIGL 2021-08-25 4.5 9.5 -83.3 -155.2
RIGL 2021-08-24 4.4 9.4 -82.4 -153.4

RIGL Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 67.78%.
  • The 2 year revenue growth rate now stands at 11280.56%.
  • Its 4 year net income to common stockholders growth rate is now at 44.71%.
Over the past 70 months, RIGL's revenue has gone up $117,490,000.

The table below shows RIGL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 149.236 5.878 -17.914
2021-09-30 147.277 9.392 -14.51
2021-06-30 144.123 0.207 -7.732
2021-03-31 133.878 -69.047 -11.487
2020-12-31 108.621 -52.185 -29.744
2020-09-30 105.571 -46.262 -27.707

RIGL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RIGL has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • RIGL's asset turnover comes in at 0.825 -- ranking 30th of 682 Pharmaceutical Products stocks.
  • GERN, NEOG, and VNDA are the stocks whose asset turnover ratios are most correlated with RIGL.

The table below shows RIGL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.825 0.994 -0.082
2021-06-30 0.886 0.994 -0.034
2021-03-31 0.912 0.992 -0.069
2020-12-31 0.844 0.992 -0.296
2020-09-30 0.765 0.993 -0.259
2020-06-30 0.739 0.991 -0.220

RIGL Price Target

For more insight on analysts targets of RIGL, see our RIGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.33 Average Broker Recommendation 1.33 (Strong Buy)

RIGL Stock Price Chart Interactive Chart >

Price chart for RIGL

RIGL Price/Volume Stats

Current price $1.25 52-week high $4.55
Prev. close $1.13 52-week low $0.64
Day low $1.11 Volume 5,027,600
Day high $1.29 Avg. volume 3,764,187
50-day MA $1.73 Dividend yield N/A
200-day MA $2.64 Market Cap 215.07M

Rigel Pharmaceuticals, Inc. (RIGL) Company Bio


Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.


RIGL Latest News Stream


Event/Time News Detail
Loading, please wait...

RIGL Latest Social Stream


Loading social stream, please wait...

View Full RIGL Social Stream

Latest RIGL News From Around the Web

Below are the latest news stories about Rigel Pharmaceuticals Inc that investors may wish to consider to help them evaluate RIGL as an investment opportunity.

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.

Yahoo | February 22, 2022

Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 25% Undervaluation?

Does the February share price for Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) reflect what it's really worth? Today, we...

Yahoo | February 22, 2022

Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 11, 2022

Shareholders in Rigel Pharmaceuticals (NASDAQ:RIGL) are in the red if they invested a year ago

Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

Yahoo | January 17, 2022

Hedge Funds Are Crazy About Rigel Pharmaceuticals, Inc. (RIGL)

In this article we are going to use hedge fund sentiment as a tool and determine whether Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a good investment right now.

Insider Monkey | January 12, 2022

Read More 'RIGL' Stories Here

RIGL Price Returns

1-mo -26.47%
3-mo -59.55%
6-mo -48.77%
1-year -71.66%
3-year -51.17%
5-year -54.21%
YTD -52.83%
2021 -24.29%
2020 63.55%
2019 -6.96%
2018 -40.72%
2017 63.03%

Continue Researching RIGL

Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:

Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5967 seconds.